United Therapeutics (UTHR) Q2 2024 earnings summary

Executive summary

• Achieved record total revenue of $715 million in Q2 2024, marking the 15th consecutive quarter of year-over-year growth, driven by strong commercial execution, innovation in drug-device combinations, and robust performance across all key products.

• Growth was led by Tyvaso, with significant contributions from Orenitram, Remodulin, and Unituxin, and supported by ongoing progress in clinical pipeline and organ manufacturing programs.

• Net income for Q2 2024 was $278.1 million, up from $259.2 million in Q2 2023, with diluted EPS rising to $5.85.

• Strategic focus spans current market-leading products, next-generation therapies in late-stage trials, and organ manufacturing for end-stage disease.

• Confidence in foundational products remains high due to unique technology and strong market position; main risks relate to late-stage clinical trial outcomes for new indications.

Financial highlights

• Total revenue reached $715 million, up 20% year-over-year from Q2 2023; net income was $278.1 million.

• Tyvaso revenue was $398.2 million, up 25% year-over-year, driven by DPI uptake, pricing, and increased utilization.

• Orenitram revenue hit $107.1 million, up 13% year-over-year, with growth from utilization, pricing, and higher average dose.

• Remodulin revenue was $147.3 million, up 16% year-over-year, maintaining leadership in parenteral prostacyclin.

• Unituxin revenue reached $52 million, up 17% year-over-year, driven by price and volume.

Outlook and guidance

• Anticipates near-term revenue growth driven by Tyvaso DPI, increased PH-ILD patient adoption, and Orenitram.

• Medium- and long-term growth expected from new products and expanded indications, pending successful clinical trials, including TETON for IPF/PPF and Ralinepag for PAH.

• Organ manufacturing and xenotransplantation programs progressing, with human clinical studies expected to commence in 2025.

• Budgeted $575 million in capital expenditures through 2026, mainly for Tyvaso DPI manufacturing expansion.

• IRA-related Medicare Part D changes may impact Tyvaso DPI and Orenitram revenues, with some offset from increased patient access.